Right of Reference and License Agreement - Additional Information (Details) - GSK Agreement $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($) shares
Research And Development Assets Acquired Other Than Through Business Combination [Line Items]
Specified clinical and regulatory milestones phase two clinical trial	$ 2.5
Maximum
Research And Development Assets Acquired Other Than Through Business Combination [Line Items]
Specified clinical and regulatory milestones	37.5
Specified sales milestone	$ 60.0
Series B Convertible Preferred Stock
Research And Development Assets Acquired Other Than Through Business Combination [Line Items]
Shares issued for asset acquisition | shares	12,500,000